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We congratulate Pe´rez de Lema et al [1] for their report
describing the beneficial effects of treatment with ACE
inhibitor or angiotensin receptor antagonist on the devel-
opment of nephritis in MRL-lpr/lpr mice. That simultane-
ous studies by our group in NZB/NZW F1 [2], MRL-lpr/
lpr [2], and NZM.2410 (our unpublished data) models of
lupus also found similar beneficial effects of treatment
with an ACE inhibitor underscores the role of the renin-
angiotensin system in the pathogenesis of lupus nephritis.
Renal protection in both studies appears to involve path-
ways that do not influence serum autoantibody levels or
renal immune complex deposition [1, 2]. In our study, a
selective reduction in chronic lesion scores that represent
renal fibrosis, but not in the glomerular activity scores that
mostly represent glomerular inflammation in NZB/NZW
F1 mice, suggests that the protection against lupus nephri-
tis probably involves mechanisms that cause tissue fibro-
sis. In that regard, type 2 cytokines that we have recently
found to promote glomerulosclerosis [3] are consistently
reduced in animals treated with the ACE inhibitor. TGF-
b1 and TGF-b2 isoforms were also selectively reduced in
certain locations in the kidneys of treated mice [2]. Ad-
ditionally, Pe´rez de Lema et al [1] found that glomerular
cellularity and renal expression of chemokines such as
CCL4 and CCL2 were reduced in animals treated with
angiotensin inhibitors. That these authors did not find a
reduction in inflammatory cell infiltrates in renal intersti-
tium of the treated animals [1] suggests that modulation
of inflammation is less likely to the primary mecha-
nism responsible for renal protection in this system. In
a previous study, MCP-1/CCL2 induced a concentration-
dependent increase in TGF-b by activated fibroblasts [4],
suggesting the possibility of indirect regulation of colla-
gen synthesis by MCP-1/CCL2 via TGF-b . Thus, we en-
vision a scenario where type 2 cytokines such as IL-4,
chemokines such as MCP-1/CCL2, and growth factors
such as TGF-b orchestrate to assemble a network that
promotes tissue fibrosis and causes chronic lupus nephri-
tis. Understanding mechanisms involved in the regulation
and counter-regulation of this network will have signif-
icant implications for the prevention of end-stage renal
disease.
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